## HUM: Humana Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.02 indicates fundamental undervaluation. Consistent execution (3/4 quarters beat estimates).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($263.63)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. Humana (NYSE:HUM) Price Target Raised to $245.00 at Barclays**
- Source: MarketBeat | 20260105T144515 | Somewhat-Bullish | Relevance: 100%
- Barclays has raised its price target for Humana (NYSE:HUM) to $245.00 from $234.00, maintaining an "equal weight" rating, which suggests a potential downside of 8.99% from the stock's previous close. This adjustment comes after Humana beat earnings and revenue estimates in its most recent quarter, reporting $3.24 EPS against an expected $2.95 and $32.65 billion in revenue. Despite mixed analyst ratings, with a consensus "Hold" and an average price target of $294.89, the company's financial performance shows strong year-over-year revenue growth.

**2. Is Weakness In Humana Inc. (NYSE:HUM) Stock A Sign That The Market Could Be Wrong Given Its Strong Financial Prospects?**
- Source: 富途牛牛 | 20260105T130815 | Somewhat-Bullish | Relevance: 100%
- Despite a recent stock decline, Humana Inc. (NYSE:HUM) exhibits strong financial prospects, supported by an impressive 18% Return on Equity (ROE), significantly above the industry average. The company's consistent earnings growth of 7.9% over the past five years, coupled with a low payout ratio suggesting substantial reinvestment, indicates a healthy financial strategy. Analysts anticipate further acceleration in earnings and a rise in future ROE to 22%, suggesting the market might be overlooking its underlying strengths.

**3. Financiere des Professionnels Fonds d investissement inc. Takes $1.67 Million Position in Humana Inc. $HUM**
- Source: MarketBeat | 20260104T113608 | Somewhat-Bullish | Relevance: 100%
- Financiere des Professionnels Fonds d'investissement initiated a new stake in Humana Inc. by purchasing 6,426 shares worth approximately $1.67 million in the third quarter. Humana surpassed Q3 earnings and revenue estimates and announced a quarterly dividend. Institutional investors hold a significant portion of Humana's stock, and analysts have a consensus target price of $294.32 for the company.

**4. Humana Inc.: Defensive Health Stock Holds Its Ground As Wall Street Reprices Medicare Risk**
- Source: AD HOC NEWS | 20260104T100214 | Neutral | Relevance: 98%
- Humana’s stock is in a tense equilibrium as investors reassess Medicare Advantage risk and margin pressures. Despite recent analyst downgrades and regulatory uncertainty, the valuation reset and stable cash flows are attracting long-term buyers. The market is waiting for evidence that management can protect margins in a challenging reimbursement and cost environment to regain broad conviction.

**5. CWA Asset Management Group LLC Raises Holdings in Humana Inc. $HUM**
- Source: MarketBeat | 20260106T095726 | Neutral | Relevance: 97%
- CWA Asset Management Group LLC significantly increased its holdings in Humana Inc. (NYSE:HUM) by 108.4% in the third quarter, bringing its total ownership to 13,195 shares valued at approximately $3.43 million. This comes as analysts provide a mixed outlook on Humana, with a consensus "Hold" rating and an average price target of $294.89, following the company's strong third-quarter earnings beat and an 11.1% revenue increase. Humana also declared a quarterly dividend of $0.885, underscoring its financial health and investor return strategy.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2026-01-05 | Barclays | $245 | $234 | +5% |
| 2025-12-18 | Morgan Stanley | $262 | $277 | -5% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2026-01-05 | Barclays | main | Equal-Weight |
| 2025-12-18 | Morgan Stanley | main | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 5 ($0.00M) |
| Sells | 5 ($1.54M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 57.3% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Vanguard Group Inc: 11.8% (-0.3%)
- Dodge & Cox Inc.: 9.4% (-0.1%)
- JPMORGAN CHASE & CO: 8.4% (+237.0%)
- Blackrock Inc.: 8.3% (-3.0%)
- State Street Corpora: 4.5% (-0.2%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_20 improving +6.0% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 1.02 suggests fair value with growth premium. Balance sheet: strong liquidity (2.0x). Insider selling cluster ($1.5M in 90 days), potential headwind. Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $33.7B |
| Beta | 0.46 |
| 52W Range | $206.87 - $315.35 |
| Short Interest | 4.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.02 |
| Forward P/E | 22.5 |
| Current P/E | 16.4 |
| YoY Growth | -27.0% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from 0.3% to 6.3% (+6.0% in 5 days), confirming momentum buildup. Currently in lower STRENGTH zone (4.0-10.0%), cross-sectional ranking at 86th percentile. MRS_5 at 4.0% confirms short-term momentum alignment. AM_20 at 7.1% shows strong absolute momentum above own 20MA. Outperforming sector by 4.6pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (1.84), confirming momentum. OFD pattern: +SUN (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 6.28% (CS: 87) | Strong |
| RSI_14 | 67.1 | Neutral |
| MACD Histogram | 1.84 | Bullish |
| vs SMA20 | 1.069x | Above |
| vs SMA50 | 1.089x | Above |
| vs SMA200 | 1.082x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $279.99
- **Stop Loss:** $263.63 (5.8% risk)
- **Target:** $312.71 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 80
- **Position Value:** $22,399.20
- **Portfolio %:** 22.40%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | RISK_ON (MEDIUM) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*RISK_ON regime with strong participation and low volatility. VIX at 14.75 (6th percentile) with breadth at 63.5% signals healthy risk appetite. Fed dovish expectations and AI/semiconductor momentum are primary drivers, though elevated put/call ratio suggests smart money hedging. Focus on quality growth with awareness of potential complacency.*

### Earnings

**Next:** 2026-02-11 (Est: $-3.89)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.83 | $3.24 | +14.6% |
| 2025Q2 | $5.87 | $6.27 | +6.9% |
| 2025Q1 | $10.07 | $11.58 | +15.0% |
| 2024Q4 | $-2.12 | $-2.16 | -1.9% |

---
*RULE-based L3 | 2026-01-07 08:25 | MRS_20*